Medtronic, Bard Secure Supplemental Medicare Reimbursement for Their New Drug-coated Balloons
Sunday, March 1, 2015
Source: Fierce Medical Devices
Medtronic ($MDT) and C.R. Bard ($BCR) announced that they have obtained supplemental Medicare reimbursement for peripheral artery disease (PAD) outpatients who are treated using their recently approved drug-coated balloons.
The federal Centers for Medicare & Medicaid Services approved pass-through payments for both of their devices. These bonus payments cover the additional cost to hospitals of treating patients with Medtronic's IN.PACT Admiral or Bard's Lutonix in an outpatient setting.
The payments are also a federal vote of confidence in drug-coated balloons in general, because CMS only approves the payments for new device categories that "substantially improve the diagnosis or treatment of an illness or injury or improve the functioning of a malformed body part compared to all available treatments or diagnostic tests," according its guidelines.